Meteorin‐like protein/METRNL/Interleukin‐41 ameliorates atopic dermatitis‐like inflammation
Allergy · 2025-02 · 80 (2) · 474-488
DOI: 10.1111/all.16150 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergy, online erschienen am 10.05.2024. Verfasst von Danqi Huang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Pathology, The Chinese University of Hong Kong, Hong Kong, China. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Inflammation, Interleukins. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Jiangsu Province Basic Research Special Fund (Natural Science Foundation), Jiangsu Provincial Department of Science and Technology, China, Innovation and Technology Commission, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Meteorin‐like protein (METRNL)/Interleukin‐41 (IL‐41) is a novel immune‐secreted cytokine/myokine involved in several inflammatory diseases. However, how METRNL exerts its regulatory properties on skin inflammation remains elusive. This study aims to elucidate the functionality and regulatory mechanism of METRNL in atopic dermatitis (AD).
Methods
METRNL levels were determined in skin and serum samples from patients with AD and subsequently verified in the vitamin D3 analogue MC903‐induced AD‐like mice model. The cellular target of METRNL activity was identified by multiplex immunostaining, single‐cell RNA‐seq and RNA‐seq.
Results
METRNL was significantly upregulated in lesions and serum of patients with dermatitis compared to healthy controls ( p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemical Pathology, The Chinese University of Hong Kong, Hong Kong, China.
- Department of Dermatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China.
- Center of Clinical Laboratory Medicine, Zhongda Hospital, Southeast University, Nanjing, China.
- Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, Germany.
- Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK, partner site Essen) and German Cancer Research Center, DKFZ, Heidelberg, Germany.
- Department of Paediatrics, The Chinese University of Hong Kong, Hong Kong, China.
ORCID-Profile: Giovanni Giglio, Ting-Fan Leung, Phyllis Fung-Yi Cheung, Chun-Kwok Wong
Förderung
- Jiangsu Province Basic Research Special Fund (Natural Science Foundation), Jiangsu Provincial Department of Science and Technology, China
- Innovation and Technology Commission
- National Natural Science Foundation of China
- Chinese University of Hong Kong
Zitieren
APA
Huang, D., Liu, X., Gao, X., Choi, C. K., Giglio, G., Farah, L., Leung, T. F., Wong, K. C., Kan, L. L., Chong, J. W., Meng, Q. J., Liao, J., Cheung, P. F., & Wong, C. K. (2025). Meteorin‐like protein/METRNL/Interleukin‐41 ameliorates atopic dermatitis‐like inflammation. Allergy, 80(2), 474-488. https://doi.org/10.1111/all.16150
Vancouver
Huang D, Liu X, Gao X, Choi CK, Giglio G, Farah L, et al. Meteorin‐like protein/METRNL/Interleukin‐41 ameliorates atopic dermatitis‐like inflammation. Allergy. 2025;80(2):474-488. doi:10.1111/all.16150
BibTeX
@article{Huang2025,
author = {Huang, Danqi and Liu, Xiuting and Gao, Xun and Choi, Chun Kit and Giglio, Giovanni and Farah, Luay and Leung, Ting-Fan and Wong, Katie Ching-Yau and Kan, Lea Ling-Yu and Chong, Jeffrey Wing-Heung and Meng, Qing-Jun and Liao, Jinyue and Cheung, Phyllis Fung-Yi and Wong, Chun-Kwok},
title = {Meteorin‐like protein/METRNL/Interleukin‐41 ameliorates atopic dermatitis‐like inflammation},
journal = {Allergy},
year = {2025},
volume = {80},
number = {2},
pages = {474--488},
doi = {10.1111/all.16150}
}
EUVIMED